{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:58:20Z","timestamp":1777733900002,"version":"3.51.4"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IHU"},{"DOI":"10.13039\/501100016394","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016394","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interdisciplinary Thematic Institute IMCBio"},{"DOI":"10.13039\/501100003768","name":"University of Strasbourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003768","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IdEx Unistra"},{"name":"EUR IMCBio"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intrahepatic cholangiocarcinoma is a public health threat because of its aggressiveness. Its genetic background differs from other biliary cancers. The aim of this study was to investigate the impact of genetic alterations on long-term outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>PubMed, MEDLINE, Scopus, and Cochrane Library databases were systematically searched for studies assessing long-term outcomes after resection of intrahepatic cholangiocarcinoma according to genetic mutational profiling until 31 May 2022. The main outcome was the impact of genetic alterations on long-term outcomes in these patients. HR (95% c.i.) was used for effect size. Publication bias was investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 24 retrospective studies were included. KRAS, IDH1\/2, and TP53 were identified as the only three genes whose mutation correlated with survival (HR: 2.476, 95% c.i. 1.67\u20133.671, P &amp;lt; 0.01 for KRAS; HR: 0.624, 95% c.i. 0.450\u20130.867, P &amp;lt; 0.01 for IDH1\/2; and HR: 2.771, 95% c.i. 2.034\u20133.775, P &amp;lt; 0.01 for TP53). The prevalence of KRAS and IDH1\/2 mutations differed between western and eastern studies (P &amp;lt; 0.001 for both genes).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Determining the overall prevalence of the most common actionable and undruggable mutations may help to expand target therapy indications in the adjuvant setting. Inconsistent results have been found for some infrequent gene alterations; their rare involvement could potentially bias their prognostic meaning.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjs\/znae257","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T08:26:23Z","timestamp":1732350383000},"source":"Crossref","is-referenced-by-count":3,"title":["Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis"],"prefix":"10.1093","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5065-6962","authenticated-orcid":false,"given":"Fabio","family":"Giannone","sequence":"first","affiliation":[{"name":"Department of Visceral and Digestive Surgery, University Hospital of Strasbourg , Strasbourg ,","place":["France"]},{"name":"Universit\u00e9 de Strasbourg, INSERM, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, U1110 , Strasbourg ,","place":["France"]},{"name":"Institut Hospitalo-Universitaire (IHU), Institute of Image-Guided Surgery , Strasbourg ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Del Zompo","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, U1110 , Strasbourg ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Saviano","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, U1110 , Strasbourg ,","place":["France"]},{"name":"Service d\u2019H\u00e9pato-gastroent\u00e9rologie, Pole H\u00e9pato-digetif, University Hospital of Strasbourg , Strasbourg ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwan","family":"Pencreach","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University Hospital of Strasbourg , Strasbourg ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Schuster","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, U1110 , Strasbourg ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F","family":"Baumert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Strasbourg, INSERM, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, U1110 , Strasbourg ,","place":["France"]},{"name":"Service d\u2019H\u00e9pato-gastroent\u00e9rologie, Pole H\u00e9pato-digetif, University Hospital of Strasbourg , Strasbourg ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Pessaux","sequence":"additional","affiliation":[{"name":"Department of Visceral and Digestive Surgery, University Hospital of Strasbourg , Strasbourg ,","place":["France"]},{"name":"Universit\u00e9 de Strasbourg, INSERM, Institut de Recherche sur les Maladies Virales et H\u00e9patiques, U1110 , Strasbourg ,","place":["France"]},{"name":"Institut Hospitalo-Universitaire (IHU), Institute of Image-Guided Surgery , Strasbourg ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"key":"2024112718254152200_znae257-B1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"2024112718254152200_znae257-B2","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1002\/cncr.32803","article-title":"Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012","volume":"126","author":"Florio","year":"2020","journal-title":"Cancer"},{"key":"2024112718254152200_znae257-B3","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.1038\/s41598-022-13605-3","article-title":"Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"2024112718254152200_znae257-B4","author":"Surveillance Research Program, National Cancer Institute"},{"key":"2024112718254152200_znae257-B5","author":"National Comprehensive Cancer Network"},{"key":"2024112718254152200_znae257-B6","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1245\/s10434-019-07353-4","article-title":"Recurrence patterns and timing courses following curative-intent resection for intrahepatic cholangiocarcinoma","volume":"26","author":"Hu","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2024112718254152200_znae257-B7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.21037\/hbsn.2019.06.12","article-title":"Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: approaching clinical practice consensus?","volume":"9","author":"Altman","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2024112718254152200_znae257-B8","doi-asserted-by":"crossref","first-page":"600027","DOI":"10.3389\/fonc.2021.600027","article-title":"Adjuvant therapy for resectable biliary tract cancer: a Bayesian network analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"2024112718254152200_znae257-B9","doi-asserted-by":"crossref","first-page":"e0229292","DOI":"10.1371\/journal.pone.0229292","article-title":"The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: a systematic review and meta-analysis","volume":"15","author":"Ke","year":"2020","journal-title":"PLoS One"},{"key":"2024112718254152200_znae257-B10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.hpb.2017.06.008","article-title":"Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis","volume":"19","author":"Reames","year":"2017","journal-title":"HPB"},{"key":"2024112718254152200_znae257-B11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"2024112718254152200_znae257-B12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.01.009","article-title":"Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies","volume":"164","author":"Edeline","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024112718254152200_znae257-B13","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"2024112718254152200_znae257-B14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"2024112718254152200_znae257-B15","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Suppl)","key":"2024112718254152200_znae257-B16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1200\/JCO.2021.39.3_suppl.265","article-title":"Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement","volume":"39","author":"Javle","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024112718254152200_znae257-B17","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024112718254152200_znae257-B18","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.18632\/oncotarget.1943","article-title":"Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups","volume":"5","author":"Simbolo","year":"2014","journal-title":"Oncotarget"},{"key":"2024112718254152200_znae257-B19","doi-asserted-by":"crossref","first-page":"e115383","DOI":"10.1371\/journal.pone.0115383","article-title":"Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications","volume":"9","author":"Churi","year":"2014","journal-title":"PLoS One"},{"key":"2024112718254152200_znae257-B20","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"2024112718254152200_znae257-B21","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1245\/s10434-015-5046-6","article-title":"Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients","volume":"23","author":"Ruzzenente","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2024112718254152200_znae257-B22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"2024112718254152200_znae257-B23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","article-title":"Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma","volume":"22","author":"Moeini","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2024112718254152200_znae257-B24","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.annonc.2021.04.012","article-title":"Practical considerations in screening for genetic alterations in cholangiocarcinoma","volume":"32","author":"Bekaii-Saab","year":"2021","journal-title":"Ann Oncol"},{"key":"2024112718254152200_znae257-B25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2024112718254152200_znae257-B26","doi-asserted-by":"crossref","first-page":"e1001419","DOI":"10.1371\/journal.pmed.1001419","article-title":"PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts","volume":"10","author":"Beller","year":"2013","journal-title":"PLoS Med"},{"key":"2024112718254152200_znae257-B27","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"2024112718254152200_znae257-B28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2024112718254152200_znae257-B29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"2024112718254152200_znae257-B30","author":"Wells"},{"key":"2024112718254152200_znae257-B31","author":"Wang"},{"key":"2024112718254152200_znae257-B32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2024112718254152200_znae257-B33","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"2024112718254152200_znae257-B34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1005412626515","article-title":"Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver","volume":"45","author":"Tannapfel","year":"2000","journal-title":"Dig Dis Sci"},{"key":"2024112718254152200_znae257-B35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gut.52.5.706","article-title":"Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma","volume":"52","author":"Tannapfel","year":"2003","journal-title":"Gut"},{"issue":"Suppl 3","key":"2024112718254152200_znae257-B36","doi-asserted-by":"crossref","first-page":"S675","DOI":"10.1245\/s10434-012-2224-7","article-title":"K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy","volume":"19","author":"Chen","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2024112718254152200_znae257-B37","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"2024112718254152200_znae257-B38","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.humpath.2013.07.026","article-title":"The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome","volume":"44","author":"Robertson","year":"2013","journal-title":"Hum Pathol"},{"key":"2024112718254152200_znae257-B39","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/onc.2012.315","article-title":"Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"key":"2024112718254152200_znae257-B40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1053\/j.gastro.2014.01.062","article-title":"Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients","volume":"146","author":"Gao","year":"2014","journal-title":"Gastroenterology"},{"key":"2024112718254152200_znae257-B41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/modpathol.2013.194","article-title":"High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases","volume":"27","author":"Jang","year":"2014","journal-title":"Mod Pathol"},{"key":"2024112718254152200_znae257-B42","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/modpathol.2013.241","article-title":"Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features","volume":"27","author":"Liau","year":"2014","journal-title":"Mod Pathol"},{"key":"2024112718254152200_znae257-B43","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","article-title":"Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets","volume":"21","author":"Zhu","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2024112718254152200_znae257-B44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12967-018-1475-x","article-title":"Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis","volume":"16","author":"Ikeno","year":"2018","journal-title":"J Transl Med"},{"key":"2024112718254152200_znae257-B45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.humpath.2017.12.028","article-title":"Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population","volume":"76","author":"Pu","year":"2018","journal-title":"Hum Pathol"},{"key":"2024112718254152200_znae257-B46","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1038\/s41598-018-25669-1","article-title":"Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma","volume":"8","author":"Simbolo","year":"2018","journal-title":"Sci Rep"},{"key":"2024112718254152200_znae257-B47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jss.2018.04.056","article-title":"IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC","volume":"231","author":"Wang","year":"2018","journal-title":"J Surg Res"},{"key":"2024112718254152200_znae257-B48","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jso.25303","article-title":"Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection","volume":"119","author":"Huang","year":"2019","journal-title":"J Surg Oncol"},{"key":"2024112718254152200_znae257-B49","doi-asserted-by":"crossref","first-page":"15820","DOI":"10.1038\/s41598-020-72810-0","article-title":"Intrahepatic cholangiocarcinomas with IDH1\/2 mutation-associated hypermethylation at selective genes and their clinicopathological features","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"key":"2024112718254152200_znae257-B50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1186\/s12885-020-06804-6","article-title":"Distinct clinical and prognostic implication of IDH1\/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Cancer"},{"key":"2024112718254152200_znae257-B51","doi-asserted-by":"crossref","first-page":"153116","DOI":"10.1016\/j.prp.2020.153116","article-title":"Target molecular treatment markers in intrahepatic cholangiocarcinoma based on Chinese population","volume":"216","author":"Pu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"2024112718254152200_znae257-B52","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41419-021-03548-4","article-title":"Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas","volume":"12","author":"Pu","year":"2021","journal-title":"Cell Death Dis"},{"key":"2024112718254152200_znae257-B53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"key":"2024112718254152200_znae257-B54","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.hpb.2022.05.1341","article-title":"Impact of FGFR2 gene fusions on survival of patients with intrahepatic cholangiocarcinoma following curative intent resection","volume":"24","author":"Buckarma","year":"2022","journal-title":"HPB"},{"key":"2024112718254152200_znae257-B55","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2020.38.4_suppl.578","article-title":"Primary versus metastatic intrahepatic cholangiocarcinoma: a comparative comprehensive genomic profiling (CGP) study","volume":"38","author":"Ross","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024112718254152200_znae257-B56","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"European Association for the Study of the Liver","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"2024112718254152200_znae257-B57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J Hepatol"},{"issue":"9","key":"2024112718254152200_znae257-B58","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"issue":"17","key":"2024112718254152200_znae257-B59","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9","key":"2024112718254152200_znae257-B60","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/onco.13844","article-title":"Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns","volume":"26","author":"Israel","year":"2021","journal-title":"The Oncologist"},{"issue":"1","key":"2024112718254152200_znae257-B61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12967-020-02437-2","article-title":"Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience","volume":"18","author":"Wang","year":"2020","journal-title":"J Transl Med"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/11\/znae257\/60833579\/znae257.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/111\/11\/znae257\/60833579\/znae257.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T18:26:09Z","timestamp":1732731969000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znae257\/7907354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,23]]},"published-print":{"date-parts":[[2024,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znae257","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,10,30]]},"article-number":"znae257"}}